Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial - PubMed (original) (raw)
Randomized Controlled Trial
doi: 10.1016/S2213-8587(19)30180-9. Epub 2019 Jun 10.
Stephen D Wiviott 2, Avivit Cahn 3, Aliza Rozenberg 3, Ilan Yanuv 3, Erica L Goodrich 2, Sabina A Murphy 2, Hiddo J L Heerspink 4, Thomas A Zelniker 2, Jamie P Dwyer 5, Deepak L Bhatt 2, Lawrence A Leiter 6, Darren K McGuire 7, John P H Wilding 8, Eri T Kato 9, Ingrid A M Gause-Nilsson 10, Martin Fredriksson 10, Peter A Johansson 10, Anna Maria Langkilde 10, Marc S Sabatine 2, Itamar Raz 3
Affiliations
- PMID: 31196815
- DOI: 10.1016/S2213-8587(19)30180-9
Randomized Controlled Trial
Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial
Ofri Mosenzon et al. Lancet Diabetes Endocrinol. 2019 Aug.
Erratum in
- Correction to Lancet Diabetes Endocrinol 2019; 7: 606-17.
[No authors listed] [No authors listed] Lancet Diabetes Endocrinol. 2019 Aug;7(8):e20. doi: 10.1016/S2213-8587(19)30221-9. Lancet Diabetes Endocrinol. 2019. PMID: 31324304 No abstract available.
Abstract
Background: Sodium-glucose co-transporter-2 (SGLT2) inhibitors have shown beneficial effects on renal outcomes mainly in patients with established atherosclerotic cardiovascular disease. Here we report analyses of renal outcomes with the SGLT2 inhibitor dapagliflozin in the DECLARE-TIMI 58 cardiovascular outcomes trial, which included patients with type 2 diabetes both with and without established atherosclerotic cardiovascular disease and mostly with preserved renal function.
Methods: In DECLARE-TIMI 58, patients with type 2 diabetes, HbA1c 6·5-12·0% (47·5-113·1 mmol/mol), with either established atherosclerotic cardiovascular disease or multiple risk factors, and creatinine clearance of at least 60 mL/min were randomly assigned (1:1) to 10 mg dapagliflozin or placebo once daily. A prespecified secondary cardiorenal composite outcome was defined as a sustained decline of at least 40% in estimated glomerular filtration rate [eGFR] to less than 60 mL/min per 1·73m2, end-stage renal disease (defined as dialysis for at least 90 days, kidney transplantation, or confirmed sustained eGFR <15mL/min per 1·73 m2), or death from renal or cardiovascular causes; a prespecified renal-specific composite outcome was the same but excluding death from cardiovascular causes. In this renal analysis, we report findings for the components of these composite outcomes, subgroup analysis of these composite outcomes, and changes in eGFR at different timepoints. DECLARE-TIMI 58 is registered with ClinicalTrials.gov, number NCT01730534.
Findings: The trial took place between April 25, 2013, and Sept 18, 2018; median follow-up was 4·2 years (IQR 3·9-4·4). Of the 17 160 participants who were randomly assigned, 8162 (47·6%) had an eGFR of at least 90 mL/min per 1·73 m2, 7732 (45·1%) had an eGFR of 60 to less than 90 mL/min per 1·73 m2, and 1265 (7·4%) had an eGFR of less than 60 mL/min per 1·73 m2 at baseline (one participant had missing data for eGFR); 6974 (40·6%) had established atherosclerotic cardiovascular disease and 10 186 (59·4%) had multiple risk factors. As previously reported, the cardiorenal secondary composite outcome was significantly reduced with dapagliflozin versus placebo (hazard ratio [HR] 0·76, 95% CI 0·67-0.87; p<0·0001); excluding death from cardiovascular causes, the HR for the renal-specific outcome was 0·53 (0·43-0·66; p<0·0001). We identified a 46% reduction in sustained decline in eGFR by at least 40% to less than 60 mL/min per 1·73 m2 (120 [1·4% vs 221 [2·6%]; HR 0·54 [95% CI 0·43-0·67]; p<0·0001). The risk of end-stage renal disease or renal death was lower in the dapagliflozin group than in the placebo group (11 [0·1%] vs 27 [0·3%]; HR 0·41 [95% CI 0·20-0·82]; p=0·012). Both the cardiorenal and renal-specific composite outcomes were improved with dapagliflozin versus placebo across various prespecified subgroups, including those defined by baseline eGFR (cardiorenal outcome pinteraction=0·97; renal-specific outcome pinteraction=0·87) and the presence or absence of established atherosclerotic cardiovascular disease (cardiorenal outcome pinteraction=0·67; renal-specific outcome pinteraction=0·72). 6 months after randomisation, the mean decrease in eGFR was larger in the dapagliflozin group than in the placebo group. The mean change equalised by 2 years, and at 3 and 4 years the mean decrease in eGFR was less with dapagliflozin than with placebo.
Interpretation: Dapagliflozin seemed to prevent and reduce progression of kidney disease compared with placebo in this large and diverse population of patients with type 2 diabetes with and without established atherosclerotic cardiovascular disease, most of whom had preserved renal function.
Funding: AstraZeneca.
Copyright © 2019 Elsevier Ltd. All rights reserved.
Comment in
- The expanding résumé of SGLT2 inhibitors.
de Boer IH. de Boer IH. Lancet Diabetes Endocrinol. 2019 Aug;7(8):585-587. doi: 10.1016/S2213-8587(19)30183-4. Epub 2019 Jun 10. Lancet Diabetes Endocrinol. 2019. PMID: 31196816 No abstract available. - Dapagliflozin reduced cardiorenal outcomes but not MACE in T2 diabetes with or at risk for atherosclerotic CVD.
Moist L. Moist L. Ann Intern Med. 2019 Oct 15;171(8):JC43. doi: 10.7326/ACPJ201910150-043. Ann Intern Med. 2019. PMID: 31610556 No abstract available. - Class effect: dapagliflozin reduces cardiovascular and kidney events.
Salehi T, Coates PT. Salehi T, et al. Kidney Int. 2020 Feb;97(2):246-248. doi: 10.1016/j.kint.2019.08.035. Epub 2019 Oct 10. Kidney Int. 2020. PMID: 31866112 No abstract available.
Similar articles
- Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
Heerspink HJL, Jongs N, Chertow GM, Langkilde AM, McMurray JJV, Correa-Rotter R, Rossing P, Sjöström CD, Stefansson BV, Toto RD, Wheeler DC, Greene T; DAPA-CKD Trial Committees and Investigators. Heerspink HJL, et al. Lancet Diabetes Endocrinol. 2021 Nov;9(11):743-754. doi: 10.1016/S2213-8587(21)00242-4. Epub 2021 Oct 4. Lancet Diabetes Endocrinol. 2021. PMID: 34619108 Clinical Trial. - Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial.
Wheeler DC, Stefánsson BV, Jongs N, Chertow GM, Greene T, Hou FF, McMurray JJV, Correa-Rotter R, Rossing P, Toto RD, Sjöström CD, Langkilde AM, Heerspink HJL; DAPA-CKD Trial Committees and Investigators. Wheeler DC, et al. Lancet Diabetes Endocrinol. 2021 Jan;9(1):22-31. doi: 10.1016/S2213-8587(20)30369-7. Lancet Diabetes Endocrinol. 2021. PMID: 33338413 Clinical Trial. - Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
Jongs N, Greene T, Chertow GM, McMurray JJV, Langkilde AM, Correa-Rotter R, Rossing P, Sjöström CD, Stefansson BV, Toto RD, Wheeler DC, Heerspink HJL; DAPA-CKD Trial Committees and Investigators. Jongs N, et al. Lancet Diabetes Endocrinol. 2021 Nov;9(11):755-766. doi: 10.1016/S2213-8587(21)00243-6. Epub 2021 Oct 4. Lancet Diabetes Endocrinol. 2021. PMID: 34619106 Clinical Trial. - Class effects of SGLT2 inhibitors on cardiorenal outcomes.
Kluger AY, Tecson KM, Lee AY, Lerma EV, Rangaswami J, Lepor NE, Cobble ME, McCullough PA. Kluger AY, et al. Cardiovasc Diabetol. 2019 Aug 5;18(1):99. doi: 10.1186/s12933-019-0903-4. Cardiovasc Diabetol. 2019. PMID: 31382965 Free PMC article. Review. - Dapagliflozin for the treatment of chronic kidney disease.
Kurata Y, Nangaku M. Kurata Y, et al. Expert Rev Endocrinol Metab. 2022 Jul;17(4):275-291. doi: 10.1080/17446651.2022.2099373. Epub 2022 Jul 13. Expert Rev Endocrinol Metab. 2022. PMID: 35822873 Review.
Cited by
- Impact of Dapagliflozin Adjunctive Therapy on the Progression of Chronic Kidney Disease in Patients with Type 2 Diabetes and Chronic Kidney Disease Stages 2-5: A systematic review and meta-analysis.
Kanimozhi M, Bisht M, Morang S, Thapliyal S, Bassan MS, Handu S. Kanimozhi M, et al. Sultan Qaboos Univ Med J. 2024 Aug;24(3):317-326. doi: 10.18295/squmj.12.2023.093. Epub 2024 Aug 29. Sultan Qaboos Univ Med J. 2024. PMID: 39234312 Free PMC article. Review. - Comparative renal outcomes of matched cohorts of patients with type 2 diabetes receiving SGLT2 inhibitors or GLP-1 receptor agonists under routine care.
Fadini GP, Longato E, Morieri ML, Bonora E, Consoli A, Fattor B, Rigato M, Turchi F, Del Prato S, Avogaro A, Solini A; DARWIN-Renal Study Investigators. Fadini GP, et al. Diabetologia. 2024 Aug 23. doi: 10.1007/s00125-024-06251-z. Online ahead of print. Diabetologia. 2024. PMID: 39177691 - Dapagliflozin treatment of patients with chronic kidney disease without diabetes across different albuminuria levels (OPTIMISE-CKD).
Svensson MK, Tangri N, Bodegård J, Adamsson Eryd S, Thuresson M, Sofue T. Svensson MK, et al. Clin Kidney J. 2024 Apr 4;17(8):sfae100. doi: 10.1093/ckj/sfae100. eCollection 2024 Aug. Clin Kidney J. 2024. PMID: 39165293 Free PMC article. - Retrospective analysis of the effect of SGLT-2 inhibitors on renal function in patients with type 2 diabetes in the real world.
Song R, Hou Q, Zhang X, Zhao W, Liu G, Li M, Zhang X, Ji L. Song R, et al. Front Pharmacol. 2024 Aug 5;15:1376850. doi: 10.3389/fphar.2024.1376850. eCollection 2024. Front Pharmacol. 2024. PMID: 39161902 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous